Get the Stockscreener App
0.706
6.49%
-0.049
After Hours:
.74
0.034
+4.82%
Azitra Inc stock is traded at $0.706, with a volume of 102.34K.
It is down -6.49% in the last 24 hours and down -12.19% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.755
Open:
$0.7556
24h Volume:
102.34K
Relative Volume:
0.04
Market Cap:
$2.49M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0314
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-4.21%
1M Performance:
-12.19%
6M Performance:
+141.78%
1Y Performance:
+35.77%
1-Day Range:
$0.7006
$0.7599
1-Week Range:
$0.68
$0.7664
52-Week Range:
$0.1305
$1.40
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.706 | 4.08M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Azitra Inc Stock (AZTR) Latest News
Phase 1b ATR-12: Azitra's engineered S. epidermidis therapy discussed at Maxim Growth Summit Oct 22-23 - Stock Titan
Is Azitra Inc. stock supported by strong fundamentals2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
Is a relief rally coming for Azitra Inc. holdersJuly 2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
What momentum shifts mean for Azitra Inc.Market Activity Report & Daily Oversold Bounce Ideas - newser.com
Why Azitra Inc stock stays undervaluedQuarterly Market Review & Long-Term Growth Portfolio Plans - newser.com
Why retail investors favor Azitra Inc. stockJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - newser.com
Custom strategy builders for tracking Azitra Inc.July 2025 Momentum & Risk Managed Investment Entry Signals - newser.com
Can Azitra Inc. recover in the next quarterWeekly Loss Report & Fast Moving Trade Plans - newser.com
O,R&L Commercial leases 12,030 s/f of biomed-tech space to Azitra - NEREJ
Azitra Inc. stock prediction for this week2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Branford-based biopharma Azitra faces de-listing from NYSE - Hartford Business Journal
Is Azitra Inc stock prepared for digital transitionWeekly Trade Report & Low Risk Entry Point Guides - newser.com
Why Azitra Inc stock stays on buy listsEarnings Growth Report & Safe Capital Growth Tips - newser.com
News impact scoring models applied to Azitra Inc.Earnings Beat & AI Enhanced Execution Alerts - newser.com
Azitra Inc Faces NYSE Compliance Deadline Notice - TipRanks
Azitra receives notice of non-compliance from NYSE American - MSN
Azitra receives NYSE American non-compliance notice By Investing.com - Investing.com Canada
Azitra receives NYSE American non-compliance notice - Investing.com India
$4M Equity Threshold: Azitra Receives NYSE Non-Compliance Notice; Plan Due Oct 31, 2025 - Stock Titan
Azitra Inc.’s ATR-04 Study: A Potential Game-Changer for Rash Treatment - TipRanks
How Azitra Inc. stock performs during Fed tightening cyclesWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
Azitra Receives Notice Of Non-Compliance From NYSE American - Barchart.com
Can machine learning forecast Azitra Inc. recoveryTreasury Yields & Fast Gaining Stock Reports - newser.com
How sentiment analysis helps forecast Azitra Inc.2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
Azitra (AZTR) Price Target Decreased by 27.99% to 12.23 - Nasdaq
What analysts say about Azitra Inc stockPortfolio Allocation Tips & We Spotted the Next Tesla – See Inside - earlytimes.in
Published on: 2025-09-30 02:04:32 - newser.com
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.09%
0.09%
Cap:
|
Volume (24h):